Equivalent Survival Between Gastric Large-Cell Neuroendocrine Carcinoma and Gastric Small-Cell Neuroendocrine Carcinoma

Overview

Journal J Clin Med

Specialty General Medicine

Date 2023 Sep 28

PMID 37762979

Authors

Zefeng Li

Hu Ren

Xiaojie Zhang

Chongyuan Sun

He Fei

Zheng Li

Chunguang Guo

Susheng Shi

Yingtai Chen

Dongbing Zhao

Affiliations

Soon will be listed here.

Abstract

Background: According to the 2019 World Health Organization (WHO) classification of gastric neuroendocrine neoplasms, gastric neuroendocrine carcinoma (GNEC) can be further divided into gastric large-cell neuroendocrine carcinoma (GLNEC) and gastric small-cell neuroendocrine carcinoma (GSNEC). Whether the prognoses of the two types have a discrepancy has long been disputed.

Method: We collected patients diagnosed with GLNEC or GSNEC in the National Cancer Center of China between January 2000 and December 2020. The characteristics and survival outcomes were compared between the two groups. We further verified our conclusion using the SEER dataset.

Results: A total of 114 GNEC patients, including 82 patients with GLNEC and 32 patients with GSNEC, have completed treatment in our hospital. Clinicopathologic differences were not observed between patients with GSNEC and GLNEC concerning the sex, age, body mass index, Charlson Comorbidity Index, tumor location, tumor size, stage, treatment received, the expression of neuroendocrine markers (CD56, Chromogranin A, synaptophysin), and score on the Ki-67 index. The 1-year, 3-year, and 5-year overall survival rates of GLNEC and GSNEC were 89.0%, 60.5%, and 52.4%, and 93.8%, 56.3%, and 52.7%, which showed no statistically significant differences. This result was confirmed further by using the SEER dataset after the inverse probability of treatment weighting.

Conclusions: Although with different cell morphology, the comparison of prognosis between the GLNEC and GSNEC has no significant statistical difference.

References

Li Z, Lu H, Chen Y, Bai X, Wang T, Fei H . Mixed large and small cell neuroendocrine carcinoma of the stomach: A case report and review of literature. World J Clin Cases. 2022; 10(16):5502-5509. PMC: 9210888. DOI: 10.12998/wjcc.v10.i16.5502. View

Sorbye H, Welin S, Langer S, Vestermark L, Holt N, Osterlund P . Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Ann Oncol. 2012; 24(1):152-60. DOI: 10.1093/annonc/mds276. View

Derks J, Speel E, Dingemans A . Adjuvant Chemotherapy in Patients With Stage I-IIIA Large-Cell Neuroendocrine Carcinoma: Should a Different Approach Be Applied Than for Small-Cell Lung Cancer?. J Clin Oncol. 2021; 39(13):1508-1509. DOI: 10.1200/JCO.20.03598. View

Zhang P, Lu M, Zeng C, Chen J, Li E, Tan H . Clinicopathological features and outcome for neuroendocrine neoplasms of gastroesophageal junction: A population-based study. Cancer Med. 2018; 7(9):4361-4370. PMC: 6143924. DOI: 10.1002/cam4.1702. View

Ishida M, Sekine S, Fukagawa T, Ohashi M, Morita S, Taniguchi H . Neuroendocrine carcinoma of the stomach: morphologic and immunohistochemical characteristics and prognosis. Am J Surg Pathol. 2013; 37(7):949-59. DOI: 10.1097/PAS.0b013e31828ff59d. View

Kinslow C, May M, Saqi A, Shu C, Chaudhary K, Wang T . Large-Cell Neuroendocrine Carcinoma of the Lung: A Population-Based Study. Clin Lung Cancer. 2019; 21(2):e99-e113. DOI: 10.1016/j.cllc.2019.07.011. View

Ajani J, DAmico T, Bentrem D, Chao J, Cooke D, Corvera C . Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022; 20(2):167-192. DOI: 10.6004/jnccn.2022.0008. View

Xie J, Sun Y, Feng C, Zheng C, Li P, Wang J . Evaluation of clinicopathological factors related to the prognosis of gastric neuroendocrine carcinoma. Eur J Surg Oncol. 2016; 42(10):1464-70. DOI: 10.1016/j.ejso.2016.08.004. View

Venizelos A, Elvebakken H, Perren A, Nikolaienko O, Deng W, Lothe I . The molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms. Endocr Relat Cancer. 2021; 29(1):1-14. PMC: 8630776. DOI: 10.1530/ERC-21-0152. View

10.

Scardoni M, Vittoria E, Volante M, Rusev B, Bersani S, Mafficini A . Mixed adenoneuroendocrine carcinomas of the gastrointestinal tract: targeted next-generation sequencing suggests a monoclonal origin of the two components. Neuroendocrinology. 2014; 100(4):310-6. DOI: 10.1159/000369071. View

11.

Xie J, Lu J, Lin J, Zheng C, Li P, Wang J . Different long-term oncologic outcomes after radical surgical resection for neuroendocrine carcinoma and adenocarcinoma of the stomach. Oncotarget. 2017; 8(34):57495-57504. PMC: 5593661. DOI: 10.18632/oncotarget.15488. View

12.

Deng Y, Chen X, Ye Y, Shi X, Zhu K, Huang L . Histological characterisation and prognostic evaluation of 62 gastric neuroendocrine carcinomas. Contemp Oncol (Pozn). 2016; 20(4):311-9. PMC: 5032160. DOI: 10.5114/wo.2016.61852. View

13.

Nagtegaal I, Odze R, Klimstra D, Paradis V, Rugge M, Schirmacher P . The 2019 WHO classification of tumours of the digestive system. Histopathology. 2019; 76(2):182-188. PMC: 7003895. DOI: 10.1111/his.13975. View

14.

Makuuchi R, Terashima M, Kusuhara M, Nakajima T, Serizawa M, Hatakeyama K . Comprehensive analysis of gene mutation and expression profiles in neuroendocrine carcinomas of the stomach. Biomed Res. 2017; 38(1):19-27. DOI: 10.2220/biomedres.38.19. View

15.

Li Z, Ren H, Zhao L, Zhang X, Wang T, Sun C . Better Prognosis of Gastric Neuroendocrine Carcinoma Than Gastric Adenocarcinoma among Whites in the United States: A Propensity Score Matching Analysis Based on SEER. Curr Oncol. 2022; 29(7):4879-4892. PMC: 9323980. DOI: 10.3390/curroncol29070387. View

16.

Liu N, Lyu J, Wang H, Sun Y, Zhang S, Lin H . Weekly Weight Gain in Women with Gestational Diabetes Mellitus and Neonatal Birth Weight - China, 2011-2021. China CDC Wkly. 2023; 5(32):703-709. PMC: 10442697. DOI: 10.46234/ccdcw2023.135. View

17.

Walter T, Tougeron D, Baudin E, le Malicot K, Lecomte T, Malka D . Poorly differentiated gastro-entero-pancreatic neuroendocrine carcinomas: Are they really heterogeneous? Insights from the FFCD-GTE national cohort. Eur J Cancer. 2017; 79:158-165. DOI: 10.1016/j.ejca.2017.04.009. View

18.

Kilinc G, Karakus O, Gurer B . The role of ASA score and Charlson comorbidity index in predicting in-hospital mortality in geriatric hip fracture patients. Eur Rev Med Pharmacol Sci. 2023; 27(15):7065-7072. DOI: 10.26355/eurrev_202308_33279. View

19.

Ishida S, Akita M, Fujikura K, Komatsu M, Sawada R, Matsumoto H . Neuroendocrine carcinoma and mixed neuroendocrine‒non-neuroendocrine neoplasm of the stomach: a clinicopathological and exome sequencing study. Hum Pathol. 2020; 110:1-10. DOI: 10.1016/j.humpath.2020.12.008. View

20.

Rindi G, Mete O, Uccella S, Basturk O, La Rosa S, Brosens L . Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms. Endocr Pathol. 2022; 33(1):115-154. DOI: 10.1007/s12022-022-09708-2. View